Emerging Diagnostic Technology: Objective Biomarkers and FDA-Cleared Tools
While existing tools represent decades of clinical and research development, they share common limitations: nearly all rely on subjective clinical observation, caregiver report, or clinician interpretation. Performance varies with the examiner’s training and experience, the child’s cooperation and communication abilities, and the accuracy of caregiver recall. These variables introduce measurement uncertainty into what should be one of the most consequential clinical decisions a family faces.
A new generation of diagnostic tools is emerging that addresses these limitations through objective, technology-based measurement of biomarkers associated with ASD.
Eye-Tracking Biomarkers
Research spanning more than two decades has established that differences in visual attention, specifically, how children look at social versus non-social information, are among the earliest and most reliable biomarkers of autism. Studies published in leading journals have demonstrated that eye-tracking technology can quantify these differences with high precision, measuring exactly where a child looks, for how long, and in what sequence as they watch carefully designed visual stimuli.
Eye-tracking technology can measure how a child aged 16–95 months visually engages with social and non-social scenes during a 12-minute video-based assessment. Collecting 120 data points per second, the system generates a report that includes a diagnostic index score and clear interpretation, indicating whether results are consistent with autism, not consistent with autism, or fall within a borderline range, along with scores across three clinically aligned domains: social disability, verbal ability, and nonverbal learning.
What makes this approach clinically significant is what it adds to the diagnostic process that traditional tools cannot provide: direct, objective measurement of the child’s actual looking behavior in real time. Unlike the ADOS-2 (which depends on examiner observation and coding), the ADI-R (which depends on caregiver recall), or the CARS-2 (which depends on clinician rating), eyetracking measures a biomarker directly from the child—eliminating the interpretive layers that introduce variability into subjective assessments.
Importantly, a trained technician such as a registered behavior technician (RBT) or medical assistant can administer the eyetracking assessment, meaning that administration does not require a PhD, MD, or the months of specialized training needed to learn how to administer instruments such as the ADOS-2 or ADI-R. The results are then reviewed and interpreted by the diagnosing clinician, who integrates the findings with clinical history, behavioral observations, and other assessment data before making a final diagnostic determination. This model allows practices to efficiently gather objective diagnostic data while ensuring that the diagnosis itself remains the responsibility of a qualified clinician, helping to reduce the specialist bottleneck that often constrains traditional evaluation models.
AI-Assisted Screening and Diagnosis
Researchers are developing artificial intelligence–based approaches that analyze behavioral data such as video of children’s interactions, movement patterns, and speech samples to identify features associated with autism. Several digital diagnostic aids using these methods have begun to receive regulatory clearance, while many other AI-based approaches remain in the research or validation phase. As the field continues to evolve, these technologies may expand the range of objective data available to clinicians and potentially support earlier and more scalable identification of autism.
Check out here for a side-by-side comparison of some of the tools discussed in this guide. This comparison covers screening instruments, gold-standard assessment tools, developmental evaluations, and technology-based diagnostic aids.
Building a Multi-Method Diagnostic Approach
The most effective diagnostic evaluations draw on multiple methods and multiple sources of information. No single tool—regardless of its psychometric properties—can capture every dimension of a complex neurodevelopmental condition like autism. The ideal assessment battery integrates at least three types of evidence:
- Caregiver-reported information: Whether gathered through a structured instrument like the ADI-R, a validated parent questionnaire, or a detailed clinical intake interview, the developmental history and current behavior as reported by caregivers provides essential context that no in-office assessment can fully replicate.
- Direct observation or behavioral measurement: Seeing how the child actually behaves—whether through ADOS-2, structured play, or technology-based measurement—provides data that is independent of caregiver perspective and captures real-time functioning.
- Developmental and cognitive profiling: Understanding the child’s broader developmental profile is essential for differential diagnosis, treatment planning, and determining whether developmental patterns are consistent with ASD or better explained by other conditions.
For ABA practices building diagnostic capacity, the question is not which single tool to adopt, but how to assemble a diagnostic approach that is clinically rigorous, operationally efficient, and accessible to the families you serve. A combination of structured intake, objective biomarker assessment, and standardized developmental evaluation can deliver comprehensive diagnostic evidence in a fraction of the time required by the traditional ADOS-2 + ADI-R battery—without sacrificing clinical quality.
Watch Our Webinar: How Two Researchers Turned Eye-Tracking Science Into a Breakthrough for Autism Diagnosis and Assessment
Frequently Asked Questions
What is the gold standard for autism diagnosis?
Historically, the combination of the ADOS-2 (direct observation) and ADI-R (caregiver interview) has been considered the gold-standard diagnostic battery, particularly in research settings. In clinical practice, comprehensive evaluations integrate multiple tools based on the child’s age, clinical presentation, and available resources. The emergence of FDA-cleared, biomarker-based tools is adding a new dimension of objective evidence to the diagnostic standard.
What is the best screening tool for autism in toddlers?
The M-CHAT-R/F is the most widely used and studied autism-specific screening tool for children aged 16 to 30 months. It has a pooled sensitivity of approximately 83% and is free for clinical use. The AAP recommends autism-specific screening at 18- and 24-month well-child visits. Broadband developmental screeners, such as the ASQ-3, can complement autism-specific screening but should not replace it.
How long does a comprehensive autism evaluation take?
Traditional comprehensive evaluations using the ADOS-2 and ADI-R can require 3 to 6 hours of clinician time spread across one or more sessions. More streamlined approaches that incorporate shorter assessment tools and objective technology can substantially reduce total evaluation time while still providing multi-method diagnostic evidence.
Can ABA practices conduct autism diagnostic evaluations?
Yes, many ABA practices are expanding into diagnostic services. Requirements vary by state, but with appropriately credentialed staff and validated assessment tools, ABA practices can offer diagnostic evaluations. Technology-based tools can be administered by a trained behavior technician, making it feasible for ABA practices to collect objective assessment data. Importantly, the results must still be reviewed, interpreted, and used to confer a diagnosis by a qualified clinician.
Related:
- Beyond Observation: Why Objective Data Is Essential for Understanding Learning
- Local SEO for ABA Therapy Providers: A Step-by-Step Guide
Like MediaFeed’s content? Be sure to follow us.
This article originally appeared on Earlipointhealth.com and was syndicated by MediaFeed.org
AlertMe
